Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

[1]  H. Sugimoto,et al.  Neuroendocrine‐like differentiation in patients with pancreatic carcinoma , 2000, Cancer.

[2]  V. Keim,et al.  Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.

[3]  V. Heinemann,et al.  CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. , 1999, Anticancer research.

[4]  J. Furuse,et al.  Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. , 1998, Hepato-gastroenterology.

[5]  M. Aapro,et al.  Gemcitabine--a safety review. , 1998, Anti-cancer drugs.

[6]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Furuse,et al.  CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.

[8]  C. Willett,et al.  CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. , 1996, American journal of surgery.

[9]  J. Robertson,et al.  A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma , 1996, Cancer.

[10]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Harris,et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.

[12]  C. Haglund,et al.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. , 1994, British Journal of Cancer.

[13]  J. Myles,et al.  Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. , 1992, Annals of surgery.

[14]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[15]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[16]  S. Steinberg,et al.  Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Schein,et al.  Chemotherapy of pancreatic carcinoma , 1984, World Journal of Surgery.

[18]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  A. Hanlon,et al.  Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. , 1998, International journal of radiation oncology, biology, physics.

[21]  W. Schlosser,et al.  Prognostic value of CA 19-9 serum course in pancreatic cancer. , 1998, Hepato-gastroenterology.

[22]  H. Gogas,et al.  Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.

[23]  W. Steinberg,et al.  Tumor Antigens in Pancreatic Cancer , 1998 .

[24]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[25]  D.,et al.  Regression Models and Life-Tables , 2022 .